| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CPUY074020 targets the histone methyltransferase G9a (EHMT2). It inhibits G9a with an IC50 of 2.18 μM. G9a is responsible for the methylation of histone H3 at lysine 9 (H3K9me2), a mark associated with transcriptional repression. By inhibiting G9a, CPUY074020 reduces H3K9me2 levels, leading to the reactivation of silenced genes and anti-proliferative effects.
|
|---|---|
| ln Vitro |
CPUY074020 (2–8μM; 24 hours) causes apoptosis in cells [1]. H3K9 trimethylation is dose-dependently deregulated by CPUY074020 (2.5–10μM; 48 hours) [1].
In vitro, CPUY074020 demonstrates potent G9a inhibitory activity with an IC50 of 2.18 μM. It also possesses anti-proliferative activity. Its activity is confirmed in cell-based assays where it reduces H3K9me2 levels and inhibits the growth of cancer cells. |
| ln Vivo |
At an oral dosage of 10 mg/kg, CPUY074020 has a T1/2 value of 4.0 hours and a 55.5% oral bioavailability, which are commendable PK characteristics [1].
In vivo, CPUY074020 is orally bioavailable. It demonstrates reasonable pharmacokinetic properties, with a half-life (T1/2) of 4.0 hours and an oral bioavailability of 55.5% at an oral dose of 10 mg/kg. Its anti-proliferative activity suggests it could be effective in animal models of cancer. |
| Enzyme Assay |
The in vitro G9a enzyme assay for CPUY074020 involves measuring its ability to inhibit G9a methyltransferase activity. The enzyme is incubated with a histone H3 peptide substrate and a methyl donor (S-adenosylmethionine, SAM) in the presence of varying concentrations of the compound. The methylation of the substrate is measured using a radioactive or fluorescence-based detection system, and the IC50 is calculated from the inhibition curve.
|
| Cell Assay |
Apoptosis analysis [1]
Cell Types: MCF-7 Cell Tested Concentrations: 2 μM, 4 μM, 8 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induced apoptosis of MCF-7 cells. Western Blot Analysis[1] Cell Types: MCF-7 Cell Tested Concentrations: 2.5 μM, 5 μM, 10 μM Incubation Duration: 48 hrs (hours) Experimental Results: Dose-dependent H3K9 trimethylation dysregulation. In vitro cell culture studies for CPUY074020 utilize cancer cell lines. Cells are treated with the compound, and the levels of H3K9me2 are measured by Western blotting to confirm target inhibition. Cell viability is assessed using an MTT or CellTiter-Glo assay. Cell cycle analysis and apoptosis detection are performed by flow cytometry. |
| Animal Protocol |
Animal/Disease Models: Mouse
Doses: 10 mg/kg Route of Administration: Oral Experimental Results:t1/2=4.0 hrs (hrs (hours)) In vivo animal experiments for CPUY074020 are performed in xenograft models of cancer. The compound is administered orally, and its effect on tumor growth is monitored. The pharmacokinetic parameters, such as half-life and oral bioavailability, are assessed. The levels of H3K9me2 in tumor tissues are measured to confirm target engagement. |
| ADME/Pharmacokinetics |
CPUY074020 has a molecular formula of C25H28N4O2 and a molecular weight of 416.52 g/mol. It is a solid compound that is soluble in DMSO. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions. It is an orally bioavailable compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for CPUY074020 are limited, as it is a research compound. It is not intended for human use. Comprehensive toxicity studies have not been reported. Standard safety precautions for handling chemical reagents should be followed. Its potent G9a inhibition suggests it could have significant epigenetic effects.
|
| References | |
| Additional Infomation |
CPUY074020 is a research compound with no clinical approval. It is a valuable tool for studying G9a biology and the role of histone methylation in gene regulation and cancer. It is used in drug discovery programs to explore the therapeutic potential of G9a inhibitors for the treatment of cancer and other diseases where epigenetic dysregulation is a factor.
|
| Molecular Formula |
C25H28N4O2
|
|---|---|
| Molecular Weight |
416.515425682068
|
| Exact Mass |
416.221
|
| CAS # |
902279-44-1
|
| PubChem CID |
20867958
|
| Appearance |
Brown to dark brown solid powder
|
| LogP |
4.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
647
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCN(CC1)C2=CC(=C3C4=C(C5=CC=CC=C5C3=O)ON=C24)NCCN6CCCC6
|
| InChi Key |
MMSYVEFXRAMWBA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H28N4O2/c30-24-17-8-2-3-9-18(17)25-22-21(24)19(26-10-15-28-11-6-7-12-28)16-20(23(22)27-31-25)29-13-4-1-5-14-29/h2-3,8-9,16,26H,1,4-7,10-15H2
|
| Chemical Name |
12-piperidin-1-yl-10-(2-pyrrolidin-1-ylethylamino)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~20 mg/mL (~48.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4008 mL | 12.0042 mL | 24.0085 mL | |
| 5 mM | 0.4802 mL | 2.4008 mL | 4.8017 mL | |
| 10 mM | 0.2401 mL | 1.2004 mL | 2.4008 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
